In vitro and in vivo assays demonstrated that CD147 silencing sensitized tumor cells to paclitaxel treatment, whereas CD147 over-expression protected tumor cells from caspase-3-mediated apoptosis induced by paclitaxel, regardless of p53 status. Here, CASP3 is linked to neoplasm.